Skip to Main Content
research
advocacy
FDA
Reporting from the frontiers of health and medicine
The Readout LOUD

Listen: An ASCO preview & another Duchenne trial failure

  • Allison DeAngelis
  • Adam Feuerstein

By Allison DeAngelis and Adam Feuerstein May 30, 2024

Reprints

Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do you pronounce bronchiectasis?

This week on “The Readout LOUD,” we preview some of the research that will be presented at the American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure.  

advertisement

To read more about Merus’ combination therapy, go here; For more on Johnson & Johnson’s mixed data, click here; For more on Nippon Shinyaku’s Duchenne drug trial failure, go here; To read more on Insmed’s bronchiectasis treatment, click here; To sign up for STAT’s ASCO newsletter, click here.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

About the Authors Reprints

Allison DeAngelis

Allison DeAngelis

Biotech Startups and Venture Capital Reporter

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast, The Readout Loud.

Tags

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.

Gilead’s twice-yearly antiviral protected women from HIV infection in…
Gilead’s twice-yearly antiviral protected women from HIV infection in large trial
The J&J lawsuit should be a wakeup call to…
The J&J lawsuit should be a wakeup call to the PBM industry — and to companies…
How Medicare leaves Puerto Ricans behind
How Medicare leaves Puerto Ricans behind
Top FDA official Peter Marks overruled staff, review team…
Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy
Ginkgo Bioworks lays off 158 employees, with more to…
Ginkgo Bioworks lays off 158 employees, with more to come
FDA approves Sarepta’s Duchenne gene therapy for nearly all…
FDA approves Sarepta’s Duchenne gene therapy for nearly all patients

Recommended Stories